References
- Anderson D (in press). http://buffalonews.com/2018/04/08/carel-jan-van-oss-94-microbiologist-saved-lives-working-with-dutch-resistance-in-world-war-ii/ (Accessed April 18, 2018).
- Brandtzaeg P. (2010). Function of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest, 39, 303–355.
- Chodon T, Koya RC, Odunsi K. (2015). Active immunotherapy of Cancer. Immunol Invest, 44, 817–836.
- Edberg SC, Bronson PM, Van Oss CJ. (1972). The valency of IgM and IgG rabbit anti-dextran antibody as a function of the size of the dextran molecule. Immunochemistry, 9, 273–288.
- Fricke I, Gabrilovich DI. (2006). Dendritic cells and tumor microenvironment: A dangerous Liaison. Immunol Invest, 35, 459–483.
- Gao Y, Zhou S, Jiang W, et al. (2003). Effects of Ganopoly® (A Ganoderma lucidum Polysaccharide Extract) on the immune functions in advanced‐stage cancer patients. Immunol Invest, 32, 201–215.
- Haile LA, Greten TF, Korangy F. (2012). Immune suppression: The hallmark of myeloid derived suppressor cells. Immunol Invest, 41, 581–594.
- Harden JL, Egilmez NK. (2012). Indoleamine 2,3-Dioxygenase and dendritic cell tolerogenicity. Immunol Invest, 41, 738–764.
- Maccalli C, Parmiani G, Ferrone S. (2017). Immunomodulating and immunoresistance properties of cancer-initiating cells: Implications for the clinical success of immunotherapy. Immunol Invest, 46, 221–238.
- Manohar A, Ahuja J, Crane JK. (2015). Immunotherapy for infectious diseases: Past, present, and future. Immunol Invest, 44, 731–737.
- Mosaad YM. (2014). Immunology of hematopoietic stem cell transplant. Immunol Invest, 43, 858–887.
- Mosayebi G, Ghazavi A, Ghasami K, et al. (2011). Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest, 40, 627–639.
- Obermajer N, Wong JL, Edwards RP, et al. (2012). PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest, 41, 635–657.
- Raber P, Ochoa AC, Rodríguez PC. (2012). Metabolism of L-Arginine by myeloid-derived suppressor cells in cancer: Mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest, 41, 614–634.
- Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z. (2011). Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest, 40, 299–338.
- Salmaninejad A, Zamani MR, Pourvahedi M, et al. (2016). Cancer/testis antigens: Expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest, 45, 619–640.
- Souza PPC, Lerner UH. (2013). The role of cytokines in inflammatory bone loss. Immunol Invest, 42, 555–622.
- Zhu W, Yu J, Nie Y, et al. (2014). Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. Immunol Invest, 43, 638–652.